Cargando…
Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combin...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/ https://www.ncbi.nlm.nih.gov/pubmed/30678447 http://dx.doi.org/10.31557/APJCP.2019.20.1.263 |
_version_ | 1783414276113825792 |
---|---|
author | Seyhoun, Iman Hajighasemlou, Saieh Ai, Jafar Hosseinzadeh, Faezeh Mirmoghtadaei, Milad Seyhoun, Seyed Moein Parseh, Benyamin Abdolahi, Shahrokh Ghazvinian, Zeinab Shadnoush, Mahdi Verdi, Javad |
author_facet | Seyhoun, Iman Hajighasemlou, Saieh Ai, Jafar Hosseinzadeh, Faezeh Mirmoghtadaei, Milad Seyhoun, Seyed Moein Parseh, Benyamin Abdolahi, Shahrokh Ghazvinian, Zeinab Shadnoush, Mahdi Verdi, Javad |
author_sort | Seyhoun, Iman |
collection | PubMed |
description | OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. METHODS: HepG2 cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare the inhibition of cell growth between the two groups with different treatments. RESULTS: The combination treatment of cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib alone (3.4 vs. 2.7 respectively). CONCLUSION: This study suggests that a combination of sorafenib with MSC-CM can synergistically suppress the growth of HCC cells. |
format | Online Article Text |
id | pubmed-6485565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-64855652019-05-13 Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells Seyhoun, Iman Hajighasemlou, Saieh Ai, Jafar Hosseinzadeh, Faezeh Mirmoghtadaei, Milad Seyhoun, Seyed Moein Parseh, Benyamin Abdolahi, Shahrokh Ghazvinian, Zeinab Shadnoush, Mahdi Verdi, Javad Asian Pac J Cancer Prev Research Article OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. METHODS: HepG2 cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare the inhibition of cell growth between the two groups with different treatments. RESULTS: The combination treatment of cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib alone (3.4 vs. 2.7 respectively). CONCLUSION: This study suggests that a combination of sorafenib with MSC-CM can synergistically suppress the growth of HCC cells. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6485565/ /pubmed/30678447 http://dx.doi.org/10.31557/APJCP.2019.20.1.263 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article Seyhoun, Iman Hajighasemlou, Saieh Ai, Jafar Hosseinzadeh, Faezeh Mirmoghtadaei, Milad Seyhoun, Seyed Moein Parseh, Benyamin Abdolahi, Shahrokh Ghazvinian, Zeinab Shadnoush, Mahdi Verdi, Javad Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title | Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title_full | Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title_fullStr | Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title_full_unstemmed | Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title_short | Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells |
title_sort | novel combination of mesenchymal stem cell-conditioned medium with sorafenib have synergistic antitumor effect of hepatocellular carcinoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/ https://www.ncbi.nlm.nih.gov/pubmed/30678447 http://dx.doi.org/10.31557/APJCP.2019.20.1.263 |
work_keys_str_mv | AT seyhouniman novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT hajighasemlousaieh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT aijafar novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT hosseinzadehfaezeh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT mirmoghtadaeimilad novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT seyhounseyedmoein novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT parsehbenyamin novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT abdolahishahrokh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT ghazvinianzeinab novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT shadnoushmahdi novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells AT verdijavad novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells |